The Harrow Health, Inc. 11.875% Senior Notes due 2027 are a series of senior unsecured debt securities issued by Harrow Health, Inc. and traded under the ticker HROWM on the Nasdaq. These notes bear interest at an annual rate of 11.875% and mature in October 2027. Proceeds from the offering were used to refinance existing indebtedness and for general corporate purposes, providing Harrow Health with additional financial flexibility to invest in its ophthalmic services network and medical products business.
Harrow Health, Inc. is a specialty healthcare company focused primarily on ophthalmology and eye care. The company’s surgical services segment encompasses a growing network of outpatient ophthalmic surgical centers that deliver laser-based treatments, cataract surgeries, and other advanced vision care procedures. These centers serve patients in diverse markets across the United States, offering same-day procedures in a cost-effective, community-based setting.
In addition to its surgical services, Harrow Health operates a medical products division dedicated to the commercialization of products and therapies for the treatment of glaucoma and other ophthalmic diseases. Through its Reliant Rx subsidiary, the company provides sales, marketing and distribution support for pharmaceutical products and devices, partnering with third-party developers to bring innovative treatments to market.
Founded in 2017 and headquartered in Fort Myers, Florida, Harrow Health has grown through both organic expansion and strategic acquisitions. Its leadership team, led by President and Chief Executive Officer Stephen D. Latta, brings extensive experience in ophthalmology, healthcare operations and capital markets. The company continues to pursue opportunities that enhance patient access to eye care and support long-term value creation for its stakeholders.
AI Generated. May Contain Errors.
MarketBeat All Access